Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 1/2016

Open Access 01-12-2016 | Review

Consensus Conference on Clinical Management of pediatric Atopic Dermatitis

Authors: Elena Galli, Iria Neri, Giampaolo Ricci, Ermanno Baldo, Maurizio Barone, Anna Belloni Fortina, Roberto Bernardini, Irene Berti, Carlo Caffarelli, Elisabetta Calamelli, Lucetta Capra, Rossella Carello, Francesca Cipriani, Pasquale Comberiati, Andrea Diociaiuti, Maya El Hachem, Elena Fontana, Michaela Gruber, Ellen Haddock, Nunzia Maiello, Paolo Meglio, Annalisa Patrizi, Diego Peroni, Dorella Scarponi, Ingrid Wielander, Lawrence F. Eichenfield

Published in: Italian Journal of Pediatrics | Issue 1/2016

Login to get access

Abstract

The Italian Consensus Conference on clinical management of atopic dermatitis in children reflects the best and most recent scientific evidence, with the aim to provide specialists with a useful tool for managing this common, but complex clinical condition. Thanks to the contribution of experts in the field and members of the Italian Society of Pediatric Allergology and Immunology (SIAIP) and the Italian Society of Pediatric Dermatology (SIDerP), this Consensus statement integrates the basic principles of the most recent guidelines for the management of atopic dermatitis to facilitate a practical approach to the disease. The therapeutical approach should be adapted to the clinical severity and requires a tailored strategy to ensure good compliance by children and their parents. In this Consensus, levels and models of intervention are also enriched by the Italian experience to facilitate a practical approach to the disease.
Literature
1.
2.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European academy of allergology and clinical immunology/ American academy of allergy, asthma and immunology/ PRACTALL consensus report. Allergy. 2006;61:969–87.PubMedCrossRef
3.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–60.PubMedCrossRef
4.
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–32.PubMedPubMedCentralCrossRef
5.
Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int. 2014;63:377–98.PubMedCrossRef
6.
Mack Correa MC, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931.
7.
Cardona ID, Kempe E, Hatzenbeuhler JR, et al. Bathing frequency recommendations for children with atopic dermatitis: result of three observational pilot surveys. Pediatr Dermatol. 2015;32(4):e194–6.PubMedCrossRef
8.
Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122:812–24.PubMedCrossRef
9.
Gutman AB, Kligman AM, Sciacca J, et al. Soak and smear. A standard technique revisited. Arch Dermatol. 2005;141:1556–9.PubMedCrossRef
10.
Hajar T, Hanifin JM, Tofte SJ, Simpson EL. Prehydration is effective for rapid control of recalcitrant atopic dermatitis. Dermatitis. 2014;25(2):56–9.PubMedPubMedCentralCrossRef
11.
Ananthapadmanabhan KP, Moore DJ, Subramanyan K, et al. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther. 2004;17 Suppl 1:16–25.PubMedCrossRef
12.
Solodkin G, Chaudhari U, Subramanyan K, et al. Benefits of mild cleansing: synthetic surfactant based (syndet) bars for patients with atopic dermatitis. Cutis. 2006;77:317–24.PubMed
13.
Hon KL, Tsang YC, Lee VW et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: A randomized, placebo-controlled cross-over trial. J Dermatolog Treat. 2016;27(2):156-62.
14.
Barnes TM, Greive KA. Use of bleach baths for the treatment of infected atopic eczema. Australas J Dermatol. 2013;54:251–8.PubMedCrossRef
15.
Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19:614–8.PubMedCrossRef
16.
Gelmetti C. La pratica dell’atopia. Ed. Springer Verlag 2008
17.
Breternitz M, Kowatzki D, Langenauer M, et al. Placebocontrolled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21:39–45.PubMedCrossRef
18.
Peris K, Valeri P, Altobelli E, et al. Efficacy evaluation of an oil-in-water emulsion (Dermoflan) in atopic dermatitis. Acta Derm Venereol. 2002;82:465–6.PubMedCrossRef
19.
Korting HC, Schollmann C, Cholcha W, et al. Efficacy and tolerability of pale sulfonated shale oil cream 4 % in the treatment of mild to moderate atopic eczema in children: a multicenter, randomized vehicle-controlled trial. J Eur Acad Dermatol Venereol. 2010;24:1176–82.PubMedCrossRef
20.
Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19:308–15.PubMed
21.
Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214:61–7.PubMedCrossRef
22.
23.
Harcharik S, Emer J. Steroid-sparing properties of emollients in dermatology. Skin Ther Lett. 2014;19:5–10.
24.
Rubel D, Thirumoorthy T, Soebaryo RW, et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013;40:160–71.PubMedCrossRef
25.
Weber TM, Samarin F, Babcock MJ, et al. Steroid-free over-the-counter eczema skin care formulations reduce risk of flare, prolong time to flare, and reduce eczema symptoms in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2015;14(5):478–85.PubMed
26.
Hon KL, Ching GK, Leung TF, et al. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010;35:22–6.PubMedCrossRef
27.
Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198–208.PubMedCrossRef
28.
Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22:73–82.PubMed
29.
Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8:1106–11.PubMed
30.
Nebus J, Wallo W. Evaluating the tolerance and efficacy of a colloidal oatmeal cream and cleanser in infants and children (ages 2 months-6 years) with atopic dermatitis. [poster P619]. Utah: Proceedings of the 34th Annual Meeting of the Society of Pediatric Dermatology, Snowbird; 2008.
31.
Kircik LH, Del Rosso JQ. Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol. 2011;4:25–31.PubMedPubMedCentral
32.
Giordano-Labadie F, Cambazard F, Guillet G, et al. Evaluation of a new moisturizer (Exomega milk) in children with atopic dermatitis. J Dermatol Treat. 2006;17:78–81.CrossRef
33.
Miller DW, Koch SB, Yentzer BA, et al. An over-thecounter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10:531–7.PubMed
34.
Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10:744–74.PubMed
35.
Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818–23.PubMedPubMedCentralCrossRef
36.
Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134:824–30.PubMedCrossRef
37.
Kvenshagen BK, Carlsen KH, Mowinckel P, et al. Can early skin care normalise dry skin and possibly prevent atopic eczema? A pilot study in young infants. Allergol Immunopathol (Madr). 2014;42:539–43.CrossRef
38.
Schario M, Lünnemann L, Stroux A, et al. Children with dry skin and atopic predisposition: daily use of emollients in a participant-blinded, randomized, prospective trial. Skin Pharmacol Physiol. 2014;27:208.PubMedCrossRef
39.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1–191.PubMed
40.
Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012;26 Suppl 6:2–8.PubMedCrossRef
41.
42.
43.
Gelmetti C, Wollenberg A. Atopic dermatitis-all you can do from the outside. Br J Dermatol. 2014;170 Suppl 1:19–24.PubMedCrossRef
44.
Ference JD, Allen RL. Choosing topical corticosteroids. Am Fam Physician. 2009;79:135–40.PubMed
45.
46.
Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55:145–63.PubMedCrossRef
47.
Thomas KS, Armstrong S, Avery A, et al. Randomized controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild to moderate atopic eczema. BMJ. 2002;324:768.PubMedPubMedCentralCrossRef
48.
Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis-an emerging concept. Allergy. 2009;64:276–8.PubMedCrossRef
49.
Chong M, Fonacier L. Treatment of eczema: corticosteroids and beyond. Clin Rev Allergy Immunol. 2015. [Epub ahead of print]
50.
Hengge UR, Ruzicka T, Schwartz RA. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15.PubMedCrossRef
51.
Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitaryadrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105:794–9.PubMedCrossRef
52.
Hong E, Smith S, Fisher G. Evaluation of atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28:393–6.PubMedCrossRef
53.
Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf. 2015;38(5):493–509.PubMedCrossRef
54.
Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1 % cream and pimecrolimus 1 % cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20:832–6.PubMedCrossRef
55.
Leung DY, Hanifin JM, Pariser DM, et al. Effects of pimecrolimus cream 1 % in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehiclecontrolled trial. Br J Dermatol. 2009;161:435–43.PubMedCrossRef
56.
Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol. 1976;112:1559–62.PubMedCrossRef
57.
Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203–21.PubMedCrossRef
58.
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–6.PubMedCrossRef
59.
Raffin D, Giraudeau B, Samimi M et al. Corticosteroid phobia among pharmacists regarding atopic derma-titis in children: a national French survey. Acta Derm Venereol. 2015; doi: 10.​2340/​00015555-2157. [Epub ahead of print]
60.
Smith SD, Hong E, Fearns S, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Austalas J Dermatol. 2010;51:168–74.CrossRef
61.
Petry V, Liphnarski G, Bessa GR, et al. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus and antibiotic resistance in patients with atopic dermatitis in Porto Alegre, Brazil. Int J Dermatol. 2014;53:731–5.PubMedCrossRef
62.
63.
Tang CS, Wang CC, Huang CF, et al. Antimicrobial susceptibility of Staphylococcus aureus in children with atopic dermatitis. Pediatr Int. 2011;53:363–7.PubMedCrossRef
64.
65.
Bonamonte D, Belloni Fortina A, Neri L, et al. Fusidic acid in skin infections and infected atopic eczema. G Ital Dermatol Venereol. 2014;149:453–9.PubMed
66.
Kircik LH. Efficacy and tolerability of retapamulin 1 % ointment for the treatment of infected atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11:858–60.PubMed
67.
Scangarella-Oman NE, Shawar RM, Bouchillon S, et al. Microbiological profile of a new topical antibacterial: retapamulin ointment 1 %. Expert Rev Anti Infect Ther. 2009;7:269–79.PubMedCrossRef
68.
Green CM, Holden CR, Gawkrodger DJ. Contact allergy to topical medicaments becomes more common with advancing age: an age-stratified study. Contact Dermatitis. 2007;56:229–31.PubMedCrossRef
69.
Sina H, Ahoyo TA, Moussaoui W, et al. Variability of antibiotic susceptibility and toxin production of Staphylococcus aureus strainsisolated from skin, soft tissues, and bone related infections. BMC Microbiol. 2013;13:188.PubMedPubMedCentralCrossRef
70.
Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Pediatr Drugs. 2013;15:303–10.CrossRef
71.
Huang X, Xu B. Efficacy and safety of tacrolimus versus pimecrolimus for the treatment of atopic dermatitis in children: a network meta-analysis. Dermatology. 2015;231(1):41–9.PubMedCrossRef
72.
Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues. J Dtsch Dermatol Ges. 2012;3:167–72.
73.
Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;7:CD009864 [Epub ahead of print].PubMed
74.
Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03 % tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicenter, comparative study. Br J Dermatol. 2008;159:1348–56.PubMedCrossRef
75.
76.
Zattra E, Albertin C, Belloni Fortina A. Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Derm Venereol. 2010;90:527.PubMedCrossRef
77.
Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–15.PubMedPubMedCentralCrossRef
78.
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163–78.PubMedPubMedCentralCrossRef
79.
Andersen RM, Thyssen JP, Maibach HI. The role of wet wrap therapy in skin disorders - a literature review. Acta Derm Venereol. 2015; doi: 10.​2340/​00015555-3134. [Epub ahead of print].
80.
Nicol NH, Boguniewicz M, Strand M, et al. Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. J Allergy Clin Immunol Pract. 2014;2:400–6.PubMedCrossRef
81.
Janmohamed SR, Oranje AP, Devillers AC, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014;70:1076–82.PubMedCrossRef
82.
Pei AY, Chan HH, Ho KM. The effectiveness of wet-wrap dressings using 0.1 % mometasone furoate and 0.005 % fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol. 2001;18:343–8.PubMedCrossRef
83.
Schnopp C, Holtmann C, Stock S, et al. Topical steroids under wet-wrap dressings in atopic dermatitis - a vehiclecontrolled trial. Dermatology. 2002;204:56–9.PubMedCrossRef
84.
Beattie PE, Lewis-Jones MS. A pilot study on the use of wet wraps in infants with moderate atopic eczema. Clin Exp Dermatol. 2004;29:348–53.PubMedCrossRef
85.
Foelster-Holst R, Nagel F, Zoellner P, et al. Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. Dermatology. 2006;212:66–9.PubMedCrossRef
86.
Devillers AC, Oranje AP. Wet-wrap treatment in children with atopic dermatitis: a practical guideline. Pediatr Dermatol. 2012;29:24–7.PubMedCrossRef
87.
Leloup P, Stalder JF, Barbarot S. Outpatient home-based wet wrap dressings with topical steroids with children with severe recalcitrant atopic dermatitis: a feasibility pilot study. Pediatr Dermatol. 2015;32(4):e177–8.PubMedCrossRef
88.
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.PubMedPubMedCentralCrossRef
89.
Schmitt J, Schäkel K, Fölster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigatorinitiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162:661–8.PubMedCrossRef
90.
Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133:429–38.PubMedCrossRef
91.
Heddle RJ, Soothill JF, Bulpitt CJ, et al. Combined oral and nasal beclomethasone dipropionate in children with atopiceczema: a randomized controlled trial. Br Med J (Clin Res Ed). 1984;289:651–4.CrossRef
92.
Slater NA, Morrell DS. Systemic therapy of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):289–99.PubMedCrossRef
93.
La Rosa M, Musarra I, Ranno C, et al. A randomized, double-blind, placebo-controlled crossover trial for systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Therap Res. 1995;56:720–4.CrossRef
94.
Galli E, Chini L, Moschese V, et al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr. 1994;83:315–7.PubMedCrossRef
95.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European academy of allergology and clinical immunology/American academy of allergy, asthma and immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2006;118:152–69.PubMedCrossRef
96.
Ricci G, Dondi A, Patrizi A, et al. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69:297–306.PubMedCrossRef
97.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327.PubMedPubMedCentralCrossRef
98.
Cotes ME, Swerlick RA. Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. Dermatol Ther. 2013;26:120–34.PubMedCrossRef
99.
Park H-Y, Kim C-R, Huh I-S, et al. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann Dermatol. 2013;25:410–6.PubMedPubMedCentralCrossRef
100.
Boguniewicz M, Sampson H, Leung SB, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001;108:651–6.PubMedCrossRef
101.
Weinberg E, Fourie B, Allmann B, et al. The use of cefadroxil in superinfected atopic dermatitis. Curr Ther Res. 1992;52:671–6.CrossRef
102.
Travers JB, Kozman A, Yao Y. Treatment outcomes of secondary impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics. Pediatr Dermatol. 2012;29:289–96.PubMedPubMedCentralCrossRef
103.
Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163:12–26.PubMedCrossRef
104.
105.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:18–55.CrossRef
106.
Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123:808–14.CrossRef
107.
Ong PY. Recurrent MRSA skin infections in atopic dermatitis. J Allergy Clin Immunol Pract. 2014;2:396–9.PubMedCrossRef
108.
109.
Berents TL, Carlsen KC, Mowinckel P, et al. Skin barrier function and staphylococcus aureus colonization in vestibulum nasi and fauces in healthy infants and infants with eczema: a population-based cohort study. PLoS One. 2015;10(6):130–45.CrossRef
110.
Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis. 2012;54:743–51.PubMedPubMedCentralCrossRef
111.
Leung DYM. Why is eczema herpeticum unexpectedly rare? Antivir Res. 2013;9:153–7.CrossRef
112.
113.
Johnson VK, Hayman JL, McCarthy CA, et al. Successful treatment of eczemacoxsackium with wet wrap therapy and low-dose topical corticosteroid. J Allergy Clin Immunol Pract. 2014;2:803–4.PubMedCrossRef
114.
115.
Luca NJC, Lara-Corrales I, Pope E. Eczema herpeticum in children: clinical features and factors predictive of hospitalization. J Pediatr. 2012;161:671–5.PubMedCrossRef
116.
Studdiford JS, Valko GP, Belin LJ, et al. Eczema herpeticum: making the diagnosis in the emergency department. J Emerg Med. 2011;40:167–9.PubMedCrossRef
117.
Wollenberg A, Zoch C, Luca NJC, et al. Eczema herpeticum in children: clinical features and factors predictive of hospitalization. J Pediatr. 2012;161:671–5.CrossRef
118.
Lange L, Alter N, Keller T, et al. Sensitization to Malassezia in infants and children with atopic dermatitis: prevalence and clinical characteristics. Allergy. 2008;63:486–7.PubMedCrossRef
119.
Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol. 2015;42(3):250–7.PubMedCrossRef
120.
Darabi K, Hostetler SG, Bechtel MA, et al. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:125–36.PubMedCrossRef
121.
Takahata Y, Sugita T, Kato H, et al. Cutaneous Malassezia flora in atopic dermatitis differs between adults and children. Br J Dermatol. 2007;157:1178–82.PubMedCrossRef
122.
Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. J Am Acad Dermatol. 2014;71:480–3.PubMedCrossRef
123.
Madan V, Griffiths CEM. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20:239–50.PubMedCrossRef
124.
Griffiths CEM, Katsambas A, Dijkmans BAC, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155 Suppl 2:1–16.PubMedCrossRef
125.
Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925–46.PubMedCrossRef
126.
Tan A, Gonzalez M. Management of severe atopic dermatitis in children. J Drugs Dermatol. 2012;11:1158–65.PubMed
127.
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–19.PubMed
128.
Sibbald C, Pope E, Ho N, et al. Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis. Pediatr Dermatol. 2015;32:36–40.PubMedCrossRef
129.
McAleer MA, Flohr C, Irvine AD. Management of difficult and severe eczema in childhood. BMJ. 2012;345, e4770.PubMedCrossRef
130.
Notaro ER, Sidbury R. Systemic Agents for Severe Atopic Dermatitis in Children. Paediatr Drugs. 2015;17(6):449-57.
131.
Garrido Colmenero C, Blasco Morente G, Torcedor Sánchez J. Oral cyclosporine weekend therapy: a new manteinance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol. 2015;32(4):551–2.PubMedCrossRef
132.
Harper JI, Ahmed IA, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52–8.PubMedCrossRef
133.
Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol. 1996;34:1016–21.PubMedCrossRef
134.
Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporine A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol. 2001;12:216–23.PubMedCrossRef
135.
Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147:308–15.PubMedCrossRef
136.
Caufiel BA, Wynnis LT. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. Am Acad Dermatol. 2013;68:29–35.CrossRef
137.
Fuggle NR, Bragoli W, Mahto A, et al. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015;72(1):108–14.PubMedPubMedCentralCrossRef
138.
Perrett CM, Walker SL, O’Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol. 2008;159:198–204.PubMedCrossRef
139.
Weathrhead SC, Wahie S, Reynolds NY. An openlabel, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156:346–51.CrossRef
140.
Tsakok T, Flohr C. Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal. Br J Dermatol. 2014;170:496–8.PubMedCrossRef
141.
El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172:351–6.PubMedCrossRef
142.
Maiello N, Longo G, Baviera G, et al. Le linee guida NICE commentate e interattive. RIAP. 2011;25(02):2–27.
143.
Proudfoot LE, Powell AM, Ayis S, et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. Br J Dermatol. 2013;169:901–9.PubMedCrossRef
144.
Van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, et al. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane Systematic review. Syst Rev. 2014;3:25.PubMedPubMedCentralCrossRef
145.
Metz M, Wahn U, Gieler U, et al. Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians. Pediatr Allergy Immunol. 2013;24:527–39.PubMedCrossRef
146.
Papoiu AD, Coghill RC, Kraft RA, et al. A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch. Neuroimage. 2012;59:3611–23.PubMedPubMedCentralCrossRef
147.
Klein PA, Clark RA. Evidence-based review of efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999;135:1522–5.PubMedCrossRef
148.
149.
150.
Ohsawa J, Hirasawa N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol Int. 2014;63(4):533–42.PubMedCrossRef
151.
ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: first results of ETAC- trial. Pediatr Allergy Immunol. 1998;9:116–24.CrossRef
152.
Simons FE, EPAAC STUDY Group. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol. 2007;18:535–42.PubMedCrossRef
153.
Jemina EA, Prema A, Thangan EB. Functional characterization of Histamine H4 receptor on human mastcells. Mol Immunol. 2014;62:19–28.CrossRef
154.
Garritsen FM, Brouwer MW, Limpens J, et al. Photo(chemo) therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170:501–13.PubMedCrossRef
155.
Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60:77–84.PubMedCrossRef
156.
Darné S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. Br J Dermatol. 2014;170:150–6.PubMedCrossRef
157.
Kwong KY, Leibel S. Update on allergen immunotherapy for treatment of allergic desease. Adv Pediatr. 2013;60:144–65.CrossRef
158.
Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper 2009. Allergy. 2009;64 Suppl 91:1–59.PubMed
159.
Calamita Z, Saconato H, Pela AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials. Allergy. 2006;61:1162–72.PubMedCrossRef
160.
Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;CD002893.
161.
Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children: meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2006;97:141–8.PubMedCrossRef
162.
Nieto A, Mazon A, Pamies R, et al. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol. 2009;124:157–61.PubMedCrossRef
163.
Gendelman SR, Lang DM. Specific immunotherapy in the treatment of atopic dermatitis: a systemic review using the Grade system. Ann Allergy Immunol. 2013;111:555–61.CrossRef
164.
Bae JM, Choi YY, Chang OK, et al. Efficacy of allergenspecific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110–7.PubMedCrossRef
165.
Wyrzykowska N, Czarnecka-Operacz M, Adamski Z. Long-term efficacy of allergen specific immunotherapy in atopic dermatitis patients in relation to quality of life. Eur Ann Allergy Clin Immunol. 2015;47(1):5–9.PubMed
166.
167.
Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep. 2011;11:277–83.PubMedCrossRef
168.
Darsow U. Allergen-specific immunotherapy for atopic eczema: updated. Curr Opin Allergy Clin Immunol. 2012;12:665–9.PubMedCrossRef
169.
Tam H, Calderon MA, Boyle RJ. Efficacy of allergen-specific immunotherapy for patients with atopic dermatitis. J Allergy Clin Immunol. 2013;132:1012–3.PubMedCrossRef
170.
Guibas GV, Makris M, Chliva C, et al. Atopic dermatitis, food allergy and dietary interventions. A tale of controversy. An Bras Dermatol. 2013;88:839–41.PubMedPubMedCentralCrossRef
171.
Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr. 1985;107:669–75.PubMedCrossRef
172.
Burks AW, Mallory SB, Williams LW, Shirrell MA. Atopic dermatitis: clinical relevance of food hypersensitivity reactions. J Pediatr. 1988;113:447–51.PubMedCrossRef
173.
Sampson HA. The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta Derm Venereol. 1992;176:34–7.
174.
Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101, e8.PubMedCrossRef
175.
Niggemann B, Sielaff B, Beyer K, et al. Outcome of double-blind, placebo-controlled food challenge tests in 107 children with atopic dermatitis. Clin Exp Allergy. 1999;29:91–6.PubMedCrossRef
176.
Eigenmann PA, Calza AM. Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis. Pediatr Allergy Immunol. 2000;11:95–100.PubMedCrossRef
177.
Lever R, MacDonald C, Waugh P, et al. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol. 1998;9:13–9.PubMedCrossRef
178.
Rancé F. What is the value of allergologic tests for the diagnosis and management of atopic dermatitis? Ann Dermatol Venereol. 2005;132:s53–63.CrossRef
179.
180.
Hill DJ, Hosking CS, de Benedictis FM, et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy. 2008;38:161–8.PubMed
181.
Bohme M, Wickman M, Lennart Nordvall S, et al. Family history and risk of atopic dermatitis in children up to 4 years. Clin Exp Allergy. 2003;33:1226–31.PubMedCrossRef
182.
Schmid-Grendelmeier P, Simon D, Simon HU, et al. Epidemiology, clinical features, and immunology of the “intrinsic” (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy. 2001;56:841–9.PubMedCrossRef
183.
Bergmann MM, Caubet JC, Boguniewicz M, et al. Evaluation of food allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1:22–8.PubMedCrossRef
184.
Werfel T, Ballmer-Weber B, Eigenmann PA, et al. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. Allergy. 2007;62:723–8.PubMedCrossRef
185.
Atherton DJ, Sewell M, Soothill JF, et al. A double-blind controlled crossover trial of an antigen-avoidance diet in atopic eczema. Lancet. 1978;1:401–3.PubMedCrossRef
186.
Sampson HA. Role of immediate food hypersensitivity in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1983;71:473–80.PubMedCrossRef
187.
Rowlands D, Tofte SJ, Hanifin JM. Does food allergy cause atopic dermatitis? Food challenge testing to dissociate eczematous from immediate reactions. Dermatol Ther. 2006;19:97–103.PubMedCrossRef
188.
Breuer K, Hetatizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy. 2004;34:817–24.PubMedCrossRef
189.
Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a populationbased, longitudinal birth cohort study. J Allergy Clin Immunol. 2008;121:872–7.PubMedCrossRef
190.
Weidinger S, O’Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 2008;121:1203–9.PubMedCrossRef
191.
Barker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127:564–7.PubMedCrossRef
192.
Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 2011;127:661–7.PubMedPubMedCentralCrossRef
193.
Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13.PubMedPubMedCentralCrossRef
194.
Fox AT, Sasieni P, du Toit G, et al. Household peanut consumption as a risk factor for the development of peanut allergy. J Allergy Clin Immunol. 2009;123:417–23.PubMedCrossRef
195.
Perry TT, Conover-Walker MK, Pomes A, et al. Distribution of peanut allergen in the environment. J Allergy Clin Immunol. 2004;113:973–6.PubMedCrossRef
196.
Dubrac S, Schmuth M, Ebner S. Atopic dermatitis: the role of Langerhans cells in disease pathogenesis. Immunol Cell Biol. 2010;88:400–9.PubMedCrossRef
197.
Bartnikas LM, Gurish MF, Burton OT, et al. Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis. J Allergy Clin Immunol. 2013;131:451-60.e1-6.
198.
Noti M, Kim BS, Siracusa MC, et al. Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. J Allergy Clin Immunol. 2014;133:1390–9.PubMedPubMedCentralCrossRef
199.
Frossard CP, Hauser C, Eigenmann PA. Antigen-specific secretory IgA antibodies in the gut are decreased in a mouse model of food allergy. J Allergy Clin Immunol. 2004;114:377–82.PubMedCrossRef
200.
Marth T, Strober W, Kelsall BL. High dose oral tolerance in ovalbumin TCR transgenic mice–systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol. 1996;157:2348–57.PubMed
201.
202.
203.
Saloga J, Renz H, Larsen GL, et al. Increased airways responsiveness in mice depends on local challenge with antigen. Am J Respir Crit Care Med. 1994;149:65–70.PubMedCrossRef
204.
Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34:2100–9.PubMedCrossRef
205.
Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Clin Exp Allergy. 2013;43:1160–70.PubMedPubMedCentralCrossRef
206.
Bertelsen RJ, Faeste CK, Granum B, et al. Food allergens in mattress dust in Norwegian homes – a potentially important source of allergen exposure. Clin Exp Allergy. 2014;44:142–9.PubMedPubMedCentralCrossRef
207.
Monti G, Muratore MC, Peltran A, et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergosorbent test to egg proteins. Clin Exp Allergy. 2002;32:1515–9.PubMedCrossRef
208.
Ibáñez MD, Escudero C. What to do with children who have never eaten egg and are egg-sensitised. Allergol Immunopathol (Madr). 2010;38:231–2.CrossRef
209.
210.
Flohr C, Perkin M, Logan K, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. J Invest Dermatol. 2014;134:345–50.PubMedPubMedCentralCrossRef
211.
Cant A, Marsden RA, Kilshaw PJ. Egg and cows’ milk hypersensitivity in exclusively breast fed infants with eczema, and detection of egg protein in breast milk. Br Med J. 1985;291:932–5.CrossRef
212.
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124 Suppl 2:r7–12.PubMedCrossRef
213.
Raulf M, Bergmann KC, Kull S, et al. Mites and other indoor allergens - from exposure to sensitization and treatment. Allergol J Int. 2015;24(3):68–80.CrossRef
214.
Langan SM, Williams HC. What causes worsening of eczema? A systemic review. Br J Dermatol. 2006;155:505–14.CrossRef
215.
216.
Utsch L, Folisi C, Akkerdaas JH, et al. Allergic sensitization is associated with inadequate anti-oxidant responses in mice and men. Allergy. 2015; doi: 10.​1111/​all.​12674. [Epub ahead of print]
217.
Klepeis NE, Nelson WC, Ott WR, et al. The National Human Activity Pattern Survey (NHAPS): a resource for assessing exposure to environmental pollutants. J Expo Anal Environ Epidemiol. 2001;11:231–52.PubMedCrossRef
218.
Brasche S, Bischof W. Daily time spent indoors in German homes–baseline data for the assessment of indoor exposure of German occupants. Int J Hyg Environ Health. 2005;208:247–53.PubMedCrossRef
219.
Bjerg A, Rönmark EP, Hagstad S, et al. Gas, dust, and fumes exposure is associated with mite sensitization and with asthma in mite-sensitized adults. Allergy. 2015;70(5):604–7.PubMedCrossRef
220.
Fuiano N, Fusilli S, Incorvaia C. House dust mite-related allergic diseases: role of skin prick test, atopy patch test, and RAST in the diagnosis of different manifestations of allergy. Eur J Pediatr. 2010;169:819–24.PubMedCrossRef
221.
Hart BJ. Life cycle and reproduction of house dust mites: environmental factors influencing mite populations. Allergy. 1998;53:13–7.PubMedCrossRef
222.
Bessot JC, Pauli G. Mite allergens: an overview. Eur Ann Allergy Clin Immunol. 2011;43:141–56.PubMed
223.
Stahl J, Paps J, Bäumer W, et al. Dermatophagoides farinae house dust mite allergen challenges reduce stratum corneum ceramides in an experimental dog model of acute atopic dermatitis. Vet Dermatol. 2012;23:497.PubMedCrossRef
224.
Kato T. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. Allergy. 2009;64:1366–74.PubMedCrossRef
225.
226.
Maeda J. House dust mite antigen in naturally occurring lesions of atopic dermatitis: the relationship between HDM antigen in the skin and HDM-sIgE antibody. J Dermatol Sci. 1992;3:73–7.PubMedCrossRef
227.
Shek LP. Specific profiles of house dust mite sensitization in children with asthma and in children with eczema. Pediatr Allergy Immunol. 2010;21:718–22.CrossRef
228.
Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol. 2000;143:379–84.PubMedCrossRef
229.
Kuehr J, Frischer T, Meinert R. Mite allergen exposure is a risk for the incidence of specific sensitization. J Allergy Clin Immunol. 1994;94:44–52.PubMedCrossRef
230.
Vervloet D, Pradal M, Porri F, et al. The epidemiology of allergy to house dust mites. Rev Mal Respir. 1991;8:59–65.PubMed
231.
Brunekreef B, Von Mutius E, Wong G, ISAAC Phase Three Study Group, et al. Exposure to cats and dogs, and symptoms of asthma, rhinoconjunctivitis, and eczema. Epidemiology. 2012;23:742–50.PubMedCrossRef
232.
Gaffin JM, Spergel JM, Boguniewicz M, et al. Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. Allergy Asthma Proc. 2012;33:282–8.PubMedPubMedCentralCrossRef
233.
234.
235.
Lee JH, Lee HS, Park MR, et al. Relationship between indoor air pollutant levels and residential environment in children with atopicdermatitis. Allergy Asthma Immunol Res. 2014;6:517–24.PubMedPubMedCentralCrossRef
236.
Bakke JV, Wieslander G, Norback D, et al. Eczema increases susceptibility to PM10 in office indoor environments. Arch Environ Occup Health. 2012;67:15–21.PubMedCrossRef
237.
Kim HH, Lee CS, Jeon JM, et al. Analysis of the association between air pollution and allergic diseases exposure from nearby sources of ambient air pollution within elementary school zones in four Korean cities. Environ Sci Pollut Res Int. 2013;20:4831–46.PubMedCrossRef
238.
Osborne NJ, Ukoumunne OC, Wake M, et al. Prevalence of eczema and food allergy is associated with latitude in Australia. J Allergy Clin Immunol. 2012;129:865–7.PubMedCrossRef
239.
Silverberg JI, Braunstein M, Lee-Wong M. Association between climate factors, pollen counts, and childhood hay fever prevalence in the United States. J Allergy Clin Immunol. 2015;135:463-469.e5.
240.
Sargen MR, Hoffstad O, Margolis DJ. Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012. J Invest Dermatol. 2014;134:51–7.PubMedPubMedCentralCrossRef
241.
Fieten KB, Weststrate ACG, van Zuuren EJ, et al. Alpine climate treatment of atopic dermatitis: a systematic review. Allergy. 2015;70(1):12–25.PubMedCrossRef
242.
Mobolaji-Lawal M, Nedorost S. The role of textiles in dermatitis: an update. Curr Allergy Asthma Rep. 2015;15(4):518.CrossRef
243.
Ricci G, Neri I, Ricci L, et al. Silk fabrics in the management of atopic dermatitis. Skin Therapy Lett. 2012;17:5–7.PubMed
244.
Ricci G, Patrizi A, Bendandi B, et al. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. Br J Dermatol. 2004;150:127–31.PubMedCrossRef
245.
Koller DY, Halmerbauer G, Bock A, et al. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. Pediatr Allergy Immunol. 2007;18:335–8.PubMedCrossRef
246.
Stinco G, Piccirillo F, Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a nonmigrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology. 2008;217:191–5.PubMedCrossRef
247.
Fontanini C, Berti I, Monasta L, et al. DermaSilk in longterm control of infantile atopic dermatitis: a double blind randomized controlled trial. G Ital Dermatol Venereol. 2013;148:293–7.PubMed
248.
Gauger A, Fischer S. Efficacy and functionality of silvercoated textiles in patients with atopic eczema. J Eur Acad Dermatol Venereol. 2006;4:265–72.
249.
Juenger M, Ladwig A, Staecker S, et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Curr Med Res Opin. 2006;22:739–50.PubMedCrossRef
250.
Wiegand C, Hipler UC, Boldt S, Strehle J, Wollina U. Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis. Clin Cosmet Investig Dermatol. 2013;6(6):115–21.PubMedPubMedCentral
251.
Lotti T, Ghersetich I. Le basi della dermocosmetologia termale. In: Caputo R, Monti M, editors. Manuale di Dermocosmetologia. Milano: Raffaello Cortina; 1995. p. 751–62.
252.
Gutenbrunner C, Bender T, Cantista P. A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology. Int J Biometeorol. 2010;54:495–507.PubMedCrossRef
253.
Even-Paz Z, Shani J. The dead sea and psoriasis. Historical and geographic background. Int J Dermatol. 1989;28:1–9.PubMedCrossRef
254.
David M, Efron D, Hodak E, et al. Treatment of psoriasis at the dead Sea: Why, how and when? Isr Med Assoc J. 2000;2:232–4.PubMed
255.
Proksch E, Nissen HP, Bremgartner M, et al. Bathing in a magnesium rich Dead Sea salt solution improves skin barrier function, enhances skin hydration and reduces inflammation in atopic dry skin. Int J Dermatol. 2005;44:151–7.PubMedCrossRef
256.
Harari M. Climatotherapy of skin diseases at the dead Sea – an update. Anales de Hidrología Médica. 2012;5:39–51.
257.
Merial-Kieny C, Mengual X, Guerrero D, et al. Clinical efficacy of Ave’ne hydrotherapy measured in a large cohort of more than 10,000 atopic or psoriatic patients. J Eur Acad Dermatol Venereol. 2011;25 Suppl 1:30–4.PubMedCrossRef
258.
Heinlin J, Schiffner-Rohe J, Schiffner R, et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrowband UVB monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol. 2011;25:765–73.PubMedCrossRef
259.
Farina S, Gisondi P, Zanoni M, et al. Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. Dermatol Treat. 2011;22:366–71.CrossRef
260.
Katz U, Shoenfeld Y, Zakin V, et al. Scientific evidence of the therapeutic effects of dead sea treatments: a systematic review. Semin Arthritis Rheum. 2012;42:186–200.PubMedCrossRef
261.
Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332:933–8.PubMedPubMedCentralCrossRef
262.
World Health Organization Regional Office for Europe Copenhagen. Therapeutic Patient Education. Continuing education programmes for health care providers in the field of prevention of chronic disease. Report for a Who Working Group. 1998.
263.
Paulo TL, Fontes Neto et al. Evaluation of emotional and Behavioral symptom in children and adolescents with atopic dermatitis. Rev Psiquiatr Rio Gd Sul. 2005; 27:3.
264.
Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics. 2003;21(2):105–13.PubMedCrossRef
265.
Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD: a new self-assessment scale in atopic dermatitis validated. Europe Allergy. 2011;66:1114–21.PubMedCrossRef
266.
Lazaurs R. Psychological stress and the coping process. New York: McGraw-Hill; 1966.
267.
Barbarot S, Bernier C, Deleuran M. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol. 2013;30(2):199–206.PubMedCrossRef
268.
Ricci G, Bendandi B, Aiazzi R, Patrizi A, Masi M. Three years of italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol. 2009;26(1):1–5.PubMedCrossRef
269.
Barone M, Galli E. Dermatite atopica ad esordio in età evolutiva e intervento psicoterapeutico complesso. Ricognizione preliminare sui presupposti teorici di un meta modello nell’ottica sistemico – relazionale. Rivista di Immunologia e Allergologia Pediatrica, 02/2014 • 41-46.
270.
271.
Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32:321–30.PubMed
272.
Warner JO, Price JF, Soothill JF, et al. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2(8096):912–5.PubMedCrossRef
273.
Di Prisco de Fuenmayor MC, Champion RH. Specific hyposensitization in atopic dermatitis. Br J Dermatol. 1979;101:697–700.PubMedCrossRef
274.
Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107:597–602.PubMedCrossRef
275.
Seidenari S, Mosca M, Taglietti M, et al. Specific hyposensitization in atopic dermatitis. Dermatologica. 1986;172:229.PubMedCrossRef
276.
Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440–6.PubMedCrossRef
277.
Heijer A. Hyposensitization with aeroallergens in atopic eczema. Allergol J. 1993;2:3–7.
278.
Galli E, Chini L, Nardi S, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol (Madr). 1994;22:18–22.
279.
Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotheraphy in children with atopic dermatitis. Rocz Akad Med Bialymst. 1995;40:414–22.PubMed
280.
Zwacka G, Glaser S, Reiger B. Therapeutische Erfahrungen mit Pangramin-SLIT im verleich zu einer subkutaneum Immunotherapie und zur symptomatichen medicamentosen Behandlung bie Kindern mit Asthma bronchiale. Rhinoconjunctivitis und Atopischer dermatitis Allergologie. 1996;19:580.
281.
Czarnecka-Operacz M, Silny W. Specific immunotherapy in atopic dermatitis--Four-year treatment in different age and airborne allergy type subgroups. Acta Dermatovenerol Croat. 2006;14:230–40.PubMed
282.
Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–70.PubMedCrossRef
283.
Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23:2503–6.PubMedCrossRef
284.
Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007;37:1277–85.PubMedCrossRef
285.
Nahm DH, Lee ES, Park HJ, et al. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008;146:235–40.PubMedCrossRef
286.
Kwon YS, Oh SH, Wu WH, et al. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy. Exp Dermatol. 2010;19:246–51.PubMedCrossRef
Metadata
Title
Consensus Conference on Clinical Management of pediatric Atopic Dermatitis
Authors
Elena Galli
Iria Neri
Giampaolo Ricci
Ermanno Baldo
Maurizio Barone
Anna Belloni Fortina
Roberto Bernardini
Irene Berti
Carlo Caffarelli
Elisabetta Calamelli
Lucetta Capra
Rossella Carello
Francesca Cipriani
Pasquale Comberiati
Andrea Diociaiuti
Maya El Hachem
Elena Fontana
Michaela Gruber
Ellen Haddock
Nunzia Maiello
Paolo Meglio
Annalisa Patrizi
Diego Peroni
Dorella Scarponi
Ingrid Wielander
Lawrence F. Eichenfield
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2016
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-016-0229-8

Other articles of this Issue 1/2016

Italian Journal of Pediatrics 1/2016 Go to the issue

Letter to the Editor

New program for identification of child maltreatment in emergency department: preliminary data

Case report

A novel p.Val244Leu mutation in MFN2 leads to Charcot-Marie-Tooth disease type 2

Case report

Antithrombotic prophylaxis in a patient with nephrotic syndrome and congenital protein S deficiency

Research

Serological evidence of acute rubella infection among under-fives in Mwanza: a threat to increasing rates of congenital rubella syndrome in Tanzania

Review

Novelty in hypertension in children and adolescents: focus on hypertension during the first year of life, use and interpretation of ambulatory blood pressure monitoring, role of physical activity in prevention and treatment, simple carbohydrates and uric acid as risk factors

Case report

Kawasaki disease and hepatobiliary involvement: report of two cases